Comparative Pharmacology
Head-to-head clinical analysis: MACRILEN versus THYREL TRH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACRILEN versus THYREL TRH.
MACRILEN vs THYREL TRH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MACRILEN (macimorelin) is a synthetic growth hormone secretagogue receptor (GHS-R) agonist that stimulates growth hormone (GH) release from the anterior pituitary. It mimics the action of ghrelin, enhancing GH secretion through GHS-R activation.
Synthetic thyrotropin-releasing hormone (TRH) that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary.
1 mg subcutaneously once daily, titrated as needed to a maximum of 2 mg daily.
Adult: 500 mcg IV bolus over 15-30 seconds; may repeat once after 15-30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours (range 2.5–4.5 hours) in healthy adults. This short half-life supports its use for diagnostic testing, with rapid clearance after stimulation of growth hormone release.
Terminal elimination half-life is approximately 5–6 minutes in healthy adults. This short half-life reflects rapid enzymatic degradation and renal clearance, requiring rapid intravenous administration for diagnostic thyroid stimulation.
Primarily renal; approximately 90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 5% is metabolized, with metabolites also eliminated renally. Fecal excretion is negligible (<2%).
Primarily renal excretion of intact TRH and metabolites (deamido-TRH and acid-TRH). Approximately 90% of administered radioactivity is recovered in urine within 24 hours. Biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Diagnostic Agent
Diagnostic Agent